Highlights

  • Radiopharm Theranostics (ASX:RAD) completed an FDA End-of-Phase 2 meeting for RAD101 in October 2026.
  • RAD101 recorded 93% concordance with MRI across evaluable lesions in its Phase 2b trial.
  • FY26 revenue from customer contracts declined to AUD 2.77 million from AUD 3.63 million.
  • FY26 net loss reached AUD 55.15 million, while year-end cash was AUD 4.14 million.

Radiopharm Theranostics Limited (ASX:RAD) is an Australian clinical-stage developer of radiopharmaceutical products intended for cancer imaging and treatment. Recent attention has centred on its RAD101 brain metastases imaging program after an October meeting with the US Food and Drug Administration (FDA), while its latest annual report illustrates the expenditure required to progress multiple trials. At the time of writing on 19 October 2026, Radiopharm shares were trading at AUD 0.005, up 12.50% during the day’s trading session.

Company Business

Radiopharm develops diagnostic and therapeutic medicines that use radioactive isotopes to image or target cancer-related biological structures. Its technology portfolio includes small molecules, peptides and monoclonal antibodies. Rather than operating an established commercial drug franchise, the company primarily undertakes research, clinical development and preparations for potential regulatory applications.

RAD101 is a fluorine-18-labelled positron emission tomography (PET) imaging candidate targeting fatty acid synthase. It is being investigated for identifying brain metastases in patients with cancer. Other development assets include RAD204, a therapeutic candidate being assessed in patients with advanced solid tumours, and BetaBart (RV-01), which entered a Phase 1/2a clinical study in February 2026. Clinical work and regulatory interaction give the company exposure to the US oncology-development environment.

Recent Development

On 5 October 2026, Radiopharm announced that it had completed an End-of-Phase 2 meeting with the FDA on RAD101. The meeting addressed planning for a pivotal development program. The company said it was undertaking Phase 3 readiness activities and expected formal FDA meeting minutes within approximately 30 days of the announcement. Receipt of those minutes, and subsequent alignment on a protocol, are distinct from trial commencement or product approval.

Previously reported interim Phase 2b data showed 93% concordance between RAD101 PET findings and MRI across evaluable lesions, meeting the specified trial primary endpoint. In September, the company said those results had been selected for a late-breaking oral presentation at the 2026 Society for Neuro-Oncology annual meeting. RAD101 also holds FDA Fast Track designation for a specified brain metastases imaging indication; the designation does not constitute marketing authorisation.

Radiopharm has disclosed a manufacturing and distribution arrangement with Siemens Healthineers for fluorine-18-labelled RAD101 doses to support a proposed US Phase 3 study. Separately, it reported a confirmed durable partial response in an ongoing Phase 1 trial of RAD204 in July. Early-stage responses require assessment in the broader clinical dataset before conclusions can be reached about treatment effectiveness.

Financial Performance and Sector Context

For the year ended 30 June 2026, revenue from customer contracts totalled AUD 2.77 million, compared with AUD 3.63 million in FY25, a decline of 23.8%. Gross profit was AUD 0.26 million, versus AUD 0.04 million in the prior year. Other income was AUD 10.73 million compared with AUD 10.26 million. The statutory loss attributable to owners increased to AUD 55.15 million from approximately AUD 36.69 million.

Research and development expenses rose to AUD 49.96 million from AUD 27.52 million, while general and administrative costs increased to AUD 16.22 million from AUD 14.64 million. Net operating cash outflow was AUD 52.78 million against AUD 36.65 million in FY25. The group reported AUD 4.14 million in cash at 30 June 2026, down from AUD 29.12 million a year earlier. FY26 net cash inflow from financing activities was AUD 33.37 million.

Its current assets totalled AUD 21.93 million and current liabilities AUD 18.90 million at year-end. The company’s financial figures reflect a clinical-stage business where trial spending, isotope supply, regulatory requirements and research activity can precede any recurring commercial product receipts. The annual report identifies research, development and commercialisation of health technologies as a single reportable segment.

Risks to Consider

The principal business risks concern clinical trial outcomes, recruitment and timing, regulatory review, radioactive-material manufacturing and distribution, and access to funds for continued development. A reported clinical endpoint does not establish that a medicine is approved or that later trials will reproduce earlier findings. The FY26 operating cash outflow and lower year-end cash balance underscore the importance of monitoring financing and working-capital developments. Equity issuance may also affect existing shareholders’ proportional interests.

What to Watch Next

The next identifiable RAD101 milestone is receipt and review of the FDA’s formal meeting minutes, followed by updates on the intended Phase 3 design and operational readiness. Further RAD204 and BetaBart trial disclosures, potential changes to the clinical timetable, cash-flow reporting and funding arrangements are also relevant. The October investor presentation provides additional context, but announced plans should be distinguished from completed clinical and regulatory steps.

Key Insights

Radiopharm’s development portfolio includes both cancer imaging and therapeutic candidates. Its October RAD101 regulatory interaction follows Phase 2b imaging results, while FY26 accounts show declining contract revenue, increased research expenditure and substantial operating cash use. Regulatory feedback, trial progress and financing remain the central areas for subsequent assessment.